Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + Lenvatinib + RT + HAIC for HCC with PVTT
NCT07776080Phase 2Recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in hepatocellular carcinoma (HCC). Primary endpoint: Progression-Free Survival at 24 months. Started Oct 2026; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07776080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776080.